India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

A new clinical trial shows that combining dapagliflozin with insulin improves kidney health and blood sugar control, and ...

Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...

Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type ...

Dapagliflozin produces a dose-dependent and sustained reduction in both fasting and postprandial serum glucose levels through increased urinary glucose excretion, ...

Dapagliflozin 10 mg also resulted in greater weight loss than did metformin (P < .0001). Events suggestive of genital infection were reported in 6.7%, 6.9%, ...

The researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio ...

Individuals treated with dapagliflozin demonstrated a reduction in FPG, a secondary endpoint, from baseline at week 24: -12.5 mg/dL for dapagliflozin 2.5 mg, -18.8 mg/dL for dapagliflozin 5 mg and ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

During follow-up, the primary outcome occurred in 16.4% of participants in the dapagliflozin group and 19.5% of participants in the placebo group, for an HR of 0.82 (95% CI, 0.73-0.92; P < .001).

Overall, there were 25 patients with adjudicated HF events. In a time-to-first-event analysis, there was no significant difference in adjudicated HF events with dapagliflozin compared with placebo, ...